News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GENEART AG: Preliminary Group Results (IFRS) for QIII/2010


11/10/2010 11:06:39 AM

REGENSBURG, GERMANY--(Marketwire - November 10, 2010) -

Geneart AG /

GENEART AG: Preliminary Group Results (IFRS) for QIII/2010

Processed and transmitted by Thomson Reuters.

The issuer is solely responsible for the content of this announcement.

* Continued stable development during the third quarter 2010

* Slightly positive operating results after nine months

* Validation of the annual prognosis 2010

GENEART AG increased its net Group sales by 13.1% during the first nine months of 2010 and thus continued its stable development of the previous quarters. Nine-month net sales increased from EUR 12.4M to EUR 14.0M. The third quarter 2010 ended with net sales of EUR 5.0M. This is an increase of 16.2% over the previous year's reference period, when EUR 4.3M were generated.

Operating performance remained largely unaffected by Applied Biosystems Deutschland GmbH's takeover. Applied Biosystems Deutschland GmbH is an indirect subsidiary of Life Technologies Corporation.

GENEART showed positive results after nine months. The preliminary operating result (EBIT in accordance with IFRS) totalled EUR 227 thousand compared to EUR 51 thousand in the prior year. The development of earnings progressed as expected. GENEART generated an EBIT of EUR 135 thousand (prior year: EUR 25 thousand) at Group level during the third quarter 2010.

The IFRS results of the first six months were affected by a one-time extraordinary item of EUR 408 thousand relating to the exercise of GENEART employee options with respect to the majority acquisition of GENEART AG by Applied Biosystems Deutschland GmbH. Adjusted for this extraordinary item, the preliminary EBIT of GENEART AG totals EUR 635 thousand after nine months.

The prognosis for the fiscal year 2010 remains valid. GENEART expects net sales in the range of EUR 19.5M, and an EBIT (in accordance with IFRS) of approx. EUR 0.5M.

Legal Information:

This document may contain estimates, prognoses and opinions about company plans and objectives, products or services, future results, opinions about these results or opinions leading up to these results. All these projections into the future are subject to risk, uncertainty and unforeseeable change outside the control of the GENEART Group. Many factors may lead to actual results, which considerably deviate from the given projections for these results.

About GENEART AG:

In 2000 GENEART entered the Gene Synthesis market and has since become the global market leader. Today, the company is one of the leading specialists in the Synthetic Biology field. Experts at GENEART provide key technologies for the development and production of new therapeutics and vaccines. Customers also take advantage of GENEART services to customize enzyme attributes, such as the attributes of enzymes used as detergent additives, and to construct bacteria, which produce complex biopolymers or break down polymers, such as synthetics, petroleum components, etc. GENEART's service portfolio ranges from the optimization and production of synthetic genes according to DIN EN ISO 9001:2008, to the generation of gene variants or complex gene libraries and the production of cell lines, to the development and production of DNA and protein based drug candidates. GENEART AG in Regensburg and its subsidiaries GENEART Inc. in Toronto (Canada) and GENEART Inc. in San Francisco (USA) employ about 180 people. The company is listed on the German Stock Exchange since May 2006. Since April 2010, U.S.-based Life Technologies Corporation, one of the leading biotechnology companies worldwide with 2009 revenues of USD 3.3B and about 9,000 employees, is the majority shareholder of GENEART AG.

[HUG#1460847]

--- End of Message ---

Geneart AG

Josef-Engert-Str.11 Regensburg Germany

Listed: Freiverkehr in Börse Stuttgart,

Freiverkehr in Börse Berlin,

Freiverkehr in Börse Düsseldorf,

Open Market (Freiverkehr) in Frankfurter Wertpapierbörse;

GENEART AG: Preliminary Group Results (IFRS) for QIII/2010: http://hugin.info/136633/R/1460847/399937.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Geneart AG via Thomson Reuters ONE


For further inquiries, please contact:

Frank Ostermair
Better Orange IR & HV AG
Haidelweg 48
81241 Munich
Germany
Phone: (0)89-8896906-10
Fax: (0)89-8896906-66
Email Contact
www.better-orange.de


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES